{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:36:38Z","timestamp":1788993398994,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-025-00914-9","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:16:47Z","timestamp":1758727007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes"],"prefix":"10.1186","volume":"25","author":[{"given":"Loup","family":"Guichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prescillia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00efse","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Alberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"914_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA A Cancer J Clin"},{"key":"914_CR2","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","volume":"20","author":"R Rouzier","year":"2002","unstructured":"Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304\u201310.","journal-title":"J Clin Oncol"},{"key":"914_CR3","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30:3960\u20136.","journal-title":"J Clin Oncol"},{"key":"914_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216\u201335.","journal-title":"Ann Oncol"},{"key":"914_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"914_CR6","volume":"1","author":"N Bromham","year":"2017","unstructured":"Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. 2017;1: CD004561.","journal-title":"Cochrane Database Syst Rev"},{"key":"914_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA"},{"key":"914_CR8","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657\u201363.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"914_CR9","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. 18FDG-PET\/CT for staging and re-staging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S-26S.","journal-title":"J Nucl Med"},{"key":"914_CR10","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"914_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","volume":"41","author":"A Cochet","year":"2014","unstructured":"Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, et al. 1\u2078F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"914_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2015.63.5185","volume":"34","author":"MG Hildebrandt","year":"2016","unstructured":"Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, et al. [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)\/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET\/CT, contrast-enhanced CT, and bone scintigraphy. J Clin Oncol. 2016;34:1889\u201397.","journal-title":"J Clin Oncol"},{"key":"914_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2967\/jnumed.111.094045","volume":"53","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53:249\u201354.","journal-title":"J Nucl Med"},{"key":"914_CR14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021;22:858\u201371.","journal-title":"Lancet Oncol"},{"key":"914_CR15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00259-014-2739-1","volume":"41","author":"O Humbert","year":"2014","unstructured":"Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, et al. HER2-positive breast cancer: 1\u2078F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1525\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"914_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-011-1780-z","volume":"131","author":"Y Wang","year":"2012","unstructured":"Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012;131:357\u201369.","journal-title":"Breast Cancer Res Treat"},{"key":"914_CR17","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"914_CR18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","volume":"38","author":"C Rousseau","year":"2011","unstructured":"Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C, et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38:1029\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"914_CR19","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","volume":"20","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Valdes Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, et al. Early assessment of axillary response with (1)(8)F-FDG PET\/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227\u201335.","journal-title":"Ann Surg Oncol"},{"key":"914_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MNM.0000000000001332","volume":"42","author":"N Akdeniz","year":"2021","unstructured":"Akdeniz N, K\u00f6mek H, K\u00fc\u00e7\u00fck\u00f6ner M, Kaplan MA, Urak\u00e7i Z, Oru\u00e7 Z, I\u015fikdo\u011fan A. The role of basal 18F-FDG PET\/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy. Nucl Med Commun. 2021;42:315\u201324.","journal-title":"Nucl Med Commun"},{"key":"914_CR21","doi-asserted-by":"crossref","unstructured":"Garcia Vicente AM, Soriano Castrej\u00f3n \u00c1, Le\u00f3n Mart\u00edn A, Relea Calatayud F, Mu\u00f1oz S\u00e1nchez Mdel M, Cruz Mora M\u00c1, et al. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET\/CT in patients with locally advanced breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:1309\u201318.","DOI":"10.1007\/s00259-013-2657-7"},{"issue":"11","key":"914_CR22","first-page":"116","volume":"22","author":"CM de Mooij","year":"2021","unstructured":"de Mooij CM, Mitea C, Mottaghy FM, Smidt ML, van Nijnatten TJA. Value of 18F-FDG PET\/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype. Eur J Nucl Med Mol Imaging Res. 2021;22(11):116.","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"issue":"12","key":"914_CR23","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00259-024-06815-6","volume":"51","author":"C Oliveira","year":"2024","unstructured":"Oliveira C, Oliveira F, Constantino C, Alves C, Brito MJ, Cardoso F, Costa DC. Baseline 18F-FDG PET\/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2024;51(12):3709\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"914_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MNM.0000000000001964","volume":"46","author":"M Lenaerts","year":"2025","unstructured":"Lenaerts M, van Amstel FJG, Mottaghy FM, Geurts SME, Tjan-Heijnen VCG, Smidt ML, van Nijnatten TJA. A review of the association between baseline [18 F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes. Nucl Med Commun. 2025;46(5):384\u201391.","journal-title":"Nucl Med Commun"},{"key":"914_CR25","doi-asserted-by":"publisher","first-page":"29388","DOI":"10.18632\/oncotarget.5001","volume":"6","author":"J Cheng","year":"2015","unstructured":"Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D. 18F-fluorodeoxyglucose (FDG) PET\/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget. 2015;6:29388\u201395.","journal-title":"Oncotarget"},{"key":"914_CR26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310:1455.","journal-title":"JAMA"},{"key":"914_CR27","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26:3502\u20139.","journal-title":"Ann Surg Oncol"},{"key":"914_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00259-013-2616-3","volume":"41","author":"O Humbert","year":"2014","unstructured":"Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"914_CR29","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.25152","volume":"116","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116:2884\u20139.","journal-title":"Cancer"},{"key":"914_CR30","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121:2544\u201352.","journal-title":"Cancer"},{"key":"914_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bulcan.2023.03.009","volume":"110","author":"C Jankowski","year":"2023","unstructured":"Jankowski C, Michel E, Vincent L, Beltjens F, Arnould L, Ladoire S, Coutant C. Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact. Bull Cancer. 2023;110:605\u201315.","journal-title":"Bull Cancer"},{"key":"914_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/jso.10090","volume":"80","author":"C Gajdos","year":"2002","unstructured":"Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol. 2002;80:4\u201311.","journal-title":"J Surg Oncol"},{"key":"914_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.21726","volume":"106","author":"BT Hennessy","year":"2006","unstructured":"Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000\u20136.","journal-title":"Cancer"},{"key":"914_CR34","first-page":"235","volume":"25","author":"F Kepenek","year":"2022","unstructured":"Kepenek F, Karao\u011flan H, Can C, K\u00f6mek H, Kaplan \u0130, Etem H, et al. The role of basal metabolic and volumetric 18F-FDG PET\/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. Hell J Nucl Med. 2022;25:235\u201346.","journal-title":"Hell J Nucl Med"},{"key":"914_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40644-017-0117-5","volume":"17","author":"MS van Ramshorst","year":"2017","unstructured":"van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, et al. Additional value of 18F-FDG PET\/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. Cancer Imaging. 2017;17:15.","journal-title":"Cancer Imaging"},{"issue":"10","key":"914_CR36","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1007\/s00259-010-1585-z","volume":"37","author":"K Dalus","year":"2010","unstructured":"Dalus K, Rendl G, Rettenbacher L, Pirich C. FDG PET\/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2010;37(10):1992\u20133. https:\/\/doi.org\/10.1007\/s00259-010-1585-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"914_CR37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0583","volume":"25","author":"S Wu","year":"2020","unstructured":"Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, et al. Subtype-guided 18 F-FDG PET\/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study. Oncologist. 2020;25: e626\u201333.","journal-title":"Oncologist"},{"issue":"9","key":"914_CR38","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024;51(9):2706\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00914-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:16:49Z","timestamp":1758727009000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00914-9","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients' non-opposition was collected at the time of inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}